I-Mab (IMAB)
NASDAQ: IMAB · IEX Real-Time Price · USD
1.800
-0.010 (-0.55%)
Apr 26, 2024, 4:30 PM EDT - Market closed
I-Mab Revenue
In the year 2023, I-Mab had annual revenue of $3.90M, a decrease of -112.27%.
Revenue (ttm)
$3.90M
Revenue Growth
-112.27%
P/S Ratio
38.31
Revenue / Employee
$10,315
Employees
378
Market Cap
149.38M USD
Revenue Chart
* The company reports in CNY currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.90M | 35.69M | -112.27% |
Dec 31, 2022 | -31.79M | -45.54M | -331.12% |
Dec 31, 2021 | 13.75M | -222.13M | -94.17% |
Dec 31, 2020 | 235.88M | 231.60M | 5,403.91% |
Dec 31, 2019 | 4.29M | -3.50M | -44.94% |
Dec 31, 2018 | 7.78M | 6.04M | 345.57% |
Dec 31, 2017 | 1.75M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
High Tide | 497.66M |
American Well | 259.05M |
Quipt Home Medical | 185.18M |
Biodesix | 49.09M |
Scilex Holding Company | 46.74M |
ClearPoint Neuro | 23.96M |
MSP Recovery | 7.71M |
IMAB News
- 23 days ago - I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference - PRNewsWire
- 25 days ago - I-Mab Announces Closing of the Divestiture of Business Operations in China - PRNewsWire
- 6 weeks ago - I-Mab Reports Full Year 2023 Financial Results and Business Update - PRNewsWire
- 2 months ago - Biotech firm I-Mab to divest China operations, shift focus to US - Reuters
- 2 months ago - I-Mab Signs Agreement to Divest its Assets and Business Operations in China - PRNewsWire
- 6 months ago - I-Mab Announces Participation at Jefferies and Piper Conferences in November - PRNewsWire
- 6 months ago - Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) - PRNewsWire
- 6 months ago - I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 - PRNewsWire